During the past decade, Bleeding and Clotting Disorders Institute conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 7 clinical trials were completed, i.e. on average, 36.8% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Bleeding and Clotting Disorders Institute" #1 sponsor was "Baxalta now part of Shire" with 10 trials, followed by "American Thrombosis and Hemostasis Network" with 3 trials sponsored, "Rigel Pharmaceuticals" with 2 trials sponsored, "Takeda" with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Bleeding and Clotting Disorders Institute" #1 collaborator was "Baxalta Innovations GmbH, now part of Shire" with 4 trials as a collaborator, "American Thrombosis and Hemostasis Network" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "BioMarin Pharmaceutical" with 1 trials as a collaborator and "Bioverativ Therapeutics Inc." with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Bleeding and Clotting Disorders Institute" are "Hemophilia A" (10 trials), "Hemophilia B" (2 trials), "Immune Thrombocytopenic Purpura" (2 trials), "Von Willebrand Disease" (2 trials) and "Von Willebrand Diseases" (2 trials). Many other conditions were trialed in "Bleeding and Clotting Disorders Institute" in a lesser frequency.

Most popular intervention types in "Bleeding and Clotting Disorders Institute" are "Drug" (13 trials), "Biological" (10 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Antihemophilic Factor (Recombinant)" (2 trials), "Antihemophilic factor, recombinant, manufactured protein-free" (2 trials), "von Willebrand factor (Recombinant)" (2 trials) and "ADVATE (Antihemophilic Factor [Recombinant])" (1 trials). Other intervention names were less common.

The vast majority of trials in "Bleeding and Clotting Disorders Institute" are 20 trials for "All" genders, 5 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Bleeding and Clotting Disorders Institute". undefined are not yet recruiting, 8 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Bleeding and Clotting Disorders Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Bleeding and Clotting Disorders Institute, 2 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".